Drosophila models of neurodegenerative diseases

Annual Review of Pathology: Mechanisms of Disease

Volumn 4, Issue , 2009, Pages 315-342

  Lu, Bingwei ^a,b   Vogel, Hannes ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Parkinson's disease; Polyglutamine disease; Prion disease

Indexed keywords

AMYLOID; ATAXIN 1; DJ 1 PROTEIN; GELDANAMYCIN; HISTONE DEACETYLASE INHIBITOR; LEVODOPA; LITHIUM; MELATONIN; PARKIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLYGLUTAMINE; PROTEIN 14 3 3; PROTEIN KINASE B; RAPAMYCIN; TAU PROTEIN; TEMSIROLIMUS; NEUROPROTECTIVE AGENT; PEPTIDE;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL DEATH; DEGENERATIVE DISEASE; DISEASE COURSE; DNA FLANKING REGION; DROSOPHILA; DRUG EFFECT; GENE; GENE EXPRESSION; GENE INTERACTION; GENETIC ASSOCIATION; GENETIC SCREENING; GENETICS; HUMAN; HUNTINGTON CHOREA; IN VIVO STUDY; MITOCHONDRION; MOLECULAR BIOLOGY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PHOSPHORYLATION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN BINDING; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SUMOYLATION; SYNAPSE; TAUOPATHY; TOXICITY; TRINUCLEOTIDE REPEAT; UBIQUITINATION; ANIMAL; DISEASE MODEL; GENOTYPE; METABOLISM; PATHOLOGY; PHENOTYPE;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DROSOPHILA; GENOTYPE; HUMANS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PEPTIDES; PHENOTYPE; SIGNAL TRANSDUCTION; TAUOPATHIES;

EID: 66149135641     PISSN: 15534006     EISSN: 15534014     Source Type: Book Series    
DOI: 10.1146/annurev.pathol.3.121806.151529     Document Type: Review

References (150)

1. Bonini NM, Fortini ME. 2003. Human neurodegenerative disease modeling using Drosophila. Annu. Rev. Neurosci. 26:627-656 (Pubitemid 37064946)
2. Muqit MM, Feany MB. 2002. Modelling neurodegenerative diseases in Drosophila: a fruitful approach? Nat. Rev. Neurosci. 3:237-243
3. Driscoll M, Gerstbrein B. 2003. Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat. Rev. Genet. 4:181-194 (Pubitemid 36267889)
4. Rogina B, Benzer S, Helfand SL. 1997. Drosophila drop-dead mutations accelerate the time course of age-related markers. Proc. Natl. Acad. Sci. USA 94:6303-6306 (Pubitemid 27270679)
5. Kretzschmar D, Hasan G, Sharma S, Heisenberg M, Benzer S. 1997. The swisscheese mutant causes glial hyperwrapping and brain degeneration in Drosophila. J. Neurosci. 17:7425-7432 (Pubitemid 27413273)
6. Akassoglou K, Malester B, Xu J, Tessarollo L, Rosenbluth J, Chao MV. 2004. Brain-specific deletion of neuropathy target esterase/swisscheese results in neurodegeneration. Proc. Natl. Acad. Sci. USA101:5075-5080 (Pubitemid 38469205)
7. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-398
8. Fernandez-Funez P, Nino-Rosales ML, de Gouyon B, She WC, Luchak JM, et al. 2000. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408:101-106 (Pubitemid 30828268)
9. Greene JC, Whitworth AJ, Kuo I, Andrews LA, Feany MB, Pallanck LJ. 2003. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc. Natl. Acad. Sci. USA 100:4078-4083 (Pubitemid 36418160)
10. Pesah Y, Pham T, Burgess H, Middlebrooks B, Verstreken P, et al. 2004. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 131:2183-2194 (Pubitemid 38702049)
11. Yang Y, Nishimura I, Imai Y, Takahashi R, Lu B. 2003. Parkin suppresses dopaminergic neuron-selective neurotoxicity induced by Pael-R in Drosophila. Neuron 37:911-924 (Pubitemid 36398298)
12. Rong YS, Golic KG. 2000. Gene targeting by homologous recombination in Drosophila. Science 288:2013-2018
13. Coulom H, Birman S. 2004. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J. Neurosci. 24:10993-10998 (Pubitemid 39602410)
14. Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. Bioessays 24:308-318
15. DeStrooper B. 2003. Aph-1, Pen-2, and Nicastrin with Presenilin generate an active γ-secretase complex. Neuron 38:9-12 (Pubitemid 36423348)
16. Haass C, De Strooper B. 1999. The presenilins in Alzheimer's disease - proteolysis holds the key. Science 286:916-919 (Pubitemid 33594023)
17. Rogaeva E, Meng Y, Lee JH, Gu Y, Kawarai T, et al. 2007. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet. 39:168-177 (Pubitemid 46184347)
18. Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297:353-356 (Pubitemid 34790756)
19. Cleveland DW, Hwo SY, Kirschner MW. 1977. Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J. Mol. Biol. 116:207-225
20. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (Tau) in Alzheimer cytoskeletal pathology. Proc. Natl. Acad. Sci. USA 83:4913-4917 (Pubitemid 16075509)
21. Greenberg SG, Davies P. 1990. A preparation of Alzheimer paired helical filaments that displays distinct tau proteins by polyacrylamide gel electrophoresis. Proc. Natl. Acad. Sci. USA 87:5827-5831 (Pubitemid 20240381)
22. Lee VM, Balin BJ, Otvos L Jr, Trojanowski JQ. 1991. A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. Science 251:675-678
23. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D'Amato CJ, Gilman S. 1997. Frontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann. Neurol. 41:706-715 (Pubitemid 27249175)
24. Hutton M, Lendon CL, Rizzu P, Baker M, Froelich S, et al. 1998. Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705 (Pubitemid 28289662)
25. Poorkaj P, Bird TD, Wijsman E, Nemens E, Garruto RM, et al. 1998. Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann. Neurol. 43:815-825 (Pubitemid 28280226)
26. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti B. 1998. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. USA 95:7737-7741 (Pubitemid 28293323)
27. Braak H, Braak E. 1991. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. (Berl.) 82:239-259
28. Mandelkow EM, Mandelkow E. 1998. Tau in Alzheimer's disease. Trends Cell Biol. 8:425-427
29. Davies P. 2000. A very incomplete comprehensive theory of Alzheimer's disease. Ann. N. Y. Acad. Sci. 924:8-16 (Pubitemid 32050176)
30. Ishihara T, Hong M, Zhang B, Nakagawa Y, Lee MK, et al. 1999. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 24:751-762
31. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, et al. 2000. Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nat. Genet. 25:402-405 (Pubitemid 32983430)
32. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. Science 293:1487-1491 (Pubitemid 32801551)
33. Gotz J, Chen F, van Dorpe J, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by Aβ 42 fibrils. Science 293:1491-1495 (Pubitemid 32807681)
34. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, et al. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron 39:409-421 (Pubitemid 36937044)
35. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM. 2004. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 43:321-332 (Pubitemid 39061125)
36. Hou CE, Carlin D, Miller BL. 2004. Non-Alzheimer's disease dementias: anatomic, clinical, and molecular correlates. Can. J. Psychiatry 49:164-171 (Pubitemid 38506494)
37. Luo L, Tully T, White K. 1992. Human amyloid precursor protein ameliorates behavioral deficit of flies deleted for Appl gene. Neuron 9:595-605
38. Ye Y, Lukinova N, Fortini ME. 1999. Neurogenic phenotypes and altered Notch processing in Drosophila Presenilin mutants. Nature 398:525-529 (Pubitemid 129523592)
39. Struhl G, Greenwald I. 1999. Presenilin is required for activity and nuclear access of Notch in Drosophila. Nature 398:522-525 (Pubitemid 129523591)
40. Gunawardena S, Goldstein LS. 2001. Disruption of axonal transport and neuronal viability by amyloid precursor protein mutations in Drosophila. Neuron 32:389-401 (Pubitemid 33082041)
41. Fossgreen A, Bruckner B, Czech C, Masters CL, Beyreuther K, Paro R. 1998. Transgenic Drosophila expressing human amyloid precursor protein show γ-secretase activity and a blistered-wing phenotype. Proc. Natl. Acad. Sci. USA 95:13703-13708 (Pubitemid 28523036)
42. Greeve I, Kretzschmar D, Tschape JA, Beyn A, Brellinger C, et al. 2004. Age-dependent neurodegeneration and Alzheimer-amyloid plaque formation in transgenic Drosophila. J. Neurosci. 24:3899-3906 (Pubitemid 38544216)
43. Finelli A, Kelkar A, Song HJ, Yang H, Konsolaki M. 2004. A model for studying Alzheimer's Aβ42- induced toxicity in Drosophila melanogaster. Mol. Cell Neurosci. 26:365-375 (Pubitemid 38968431)
44. IijimaK, Liu HP, Chiang AS, Hearn SA, Konsolaki M, Zhong Y. 2004. Dissecting the pathological effects of human Aβ40 and Aβ42 in Drosophila: a potential model for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 101:6623-6628 (Pubitemid 38586024)
45. Williams DW, Tyrer M, Shepherd D. 2000. Tau and tau reporters disrupt central projections of sensory neurons in Drosophila. J. Comp. Neurol. 428:630-640 (Pubitemid 30842359)
46. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, et al. 2001. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293:711-714 (Pubitemid 32728676)
47. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, et al. 2002. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 34:509-519 (Pubitemid 34628749)
48. Mershin A, Pavlopoulos E, Fitch O, Braden BC, Nanopoulos DV, Skoulakis EM. 2004. Learning and memory deficits upon TAU accumulation in Drosophila mushroom body neurons. Learn. Mem. 11:277-287 (Pubitemid 38697893)
49. Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24:1121-1159
50. Nishimura I, Yang Y, Lu B. 2004. PAR-1 kinase plays an initiator role in a temporally ordered phosphorylation process that confers tau toxicity in Drosophila. Cell 116:671-682 (Pubitemid 38326726)
51. Guo S, Kemphues KJ. 1995. par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed. Cell 81:611-620
52. Drewes G, Ebneth A, Preuss U, Mandelkow EM, Mandelkow E. 1997. MARK, a novel family of protein kinases that phosphorylate microtubule-associated proteins and trigger microtubule disruption. Cell 89:297-308 (Pubitemid 27199901)
53. Bohm H, Brinkmann V, Drab M, Henske A, Kurzchalia TV. 1997. Mammalian homologues of C. elegans PAR-1 are asymmetrically localized in epithelial cells and may influence their polarity. Curr. Biol. 7:603-606 (Pubitemid 27335656)
54. Biernat J, Wu YZ, Timm T, Zheng-Fischhofer Q, Mandelkow E, et al. 2002. Protein kinase MARK/PAR- 1 is required for neurite outgrowth and establishment of neuronal polarity. Mol. Biol. Cell 13:4013-4028 (Pubitemid 35398567)
55. Shulman JM, Feany MB. 2003. Genetic modifiers of tauopathy in Drosophila. Genetics 165:1233-1242
56. Cummings CJ, Reinstein E, Sun Y, Antalffy B, Jiang Y, et al. 1999. Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice. Neuron 24:879-892 (Pubitemid 30017667)
57. Hanger DP, Betts JC, Loviny TL, Blackstock WP, Anderton BH. 1998. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J. Neurochem. 71:2465-2476
58. Wang JW, Imai Y, Lu B. 2007. Activation of PAR-1 kinase and stimulation of tau phosphorylation by diverse signals require the tumor-suppressor protein LKB1. J. Neurosci. 27:574-581 (Pubitemid 46143761)
59. Augustinack JC, Schneider A, Mandelkow EM, Hyman BT. 2002. Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease. Acta Neuropathol. (Berl.) 103:26-35 (Pubitemid 36075309)
60. Perez M, Ribe E, Rubio A, Lim F, Moran MA, et al. 2005. Characterization of a double (amyloid precursor protein-tau) transgenic: tau phosphorylation and aggregation. Neuroscience 130:339-347 (Pubitemid 40125472)
61. Selkoe DJ. 2002. Alzheimer's disease is a synaptic failure. Science 298:789-791
62. Wang P, Yang G, Mosier DR, Chang P, Zaidi T, et al. 2005. Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-like protein 2. J. Neurosci. 25:1219-1225 (Pubitemid 40268964)
63. Ashe KH. 2000. Synaptic structure and function in transgenic APP mice. Ann. N. Y. Acad. Sci. 924:39-41
64. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. 2007. Reducing endogenous tau ameliorates amyloid β-induced deficits in an Alzheimer's disease mouse model. Science 316:750-754 (Pubitemid 46717684)
65. Chee FC, Mudher A, Cuttle MF, Newman TA, MacKay D, et al. 2005. Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol. Dis. 20:918-928 (Pubitemid 41619367)
66. Yoshiyama Y, Higuchi M, Zhang B, Huang SM, Iwata N, et al. 2007. Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:337-351 (Pubitemid 46161268)
67. Zhang Y, Guo H, Kwan H, Wang JW, Kosek J, Lu B. 2007. PAR-1 kinase phosphorylates Dlg and regulates its postsynaptic targeting at the Drosophila neuromuscular junction. Neuron 53:201-215 (Pubitemid 46074401)
68. Almeida CG, Tampellini D, Takahashi RH, Greengard P, Lin MT, et al. 2005. β-amyloid accumulation in APP mutant neurons reduces PSD-95 and GluR1 in synapses. Neurobiol. Dis. 20:187-198 (Pubitemid 41476246)
69. Gylys KH, Fein JA, Yang F, Wiley DJ, Miller CA, Cole GM. 2004. Synaptic changes in Alzheimer's disease: Increased amyloid-β and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence. Am. J. Pathol. 165:1809-1817 (Pubitemid 39435178)
70. Roselli F, Tirard M, Lu J, Hutzler P, Lamberti P, et al. 2005. Soluble β-amyloid 1-40 induces NMDA-dependent degradation of postsynaptic density-95 at glutamatergic synapses. J. Neurosci. 25:11061-11070 (Pubitemid 43089551)
71. Dexter DT, Sian J, Rose S, Hindmarsh JG, Mann VM, et al. 1994. Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann. Neurol. 35:38-44 (Pubitemid 24027604)
72. Dunnett SB, Bjorklund A. 1999. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399:A32-39 (Pubitemid 129519186)
73. Zhang Y, Dawson VL, Dawson TM. 2000. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol. Dis. 7:240-250
74. Jenner P. 2003. Oxidative stress in Parkinson's disease. Ann. Neurol. 53(Suppl. 3):S26-38
75. Beal MF. 2001. Experimental models of Parkinson's disease. Nat. Rev. Neurosci. 2:325-334
76. Bertoli-Avella AM, Oostra BA, Heutink P. 2004. Chasing genes in Alzheimer's and Parkinson's disease. Hum. Genet. 114:413-438 (Pubitemid 38678920)
77. Dawson TM, Dawson VL. 2003. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302:819-822 (Pubitemid 37339614)
78. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. 1997. Mutation in the α-Synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047 (Pubitemid 27443610)
79. Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, et al. 1998. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392:605-608 (Pubitemid 28207717)
80. Leroy E, Boyer R, Auburger G, Leube B, Ulm G, et al. 1998. The ubiquitin pathway in Parkinson's disease. Nature 395:451-452
81. Bonifati V, Rizzu P, Squitieri F, Krieger E, Vanacore N, et al. 2003. DJ-1(PARK7), a novel gene for autosomal recessive, early-onset parkinsonism. Neurol. Sci. 24:159-160 (Pubitemid 37304291)
82. Valente EM, Abou-Sleiman PM, Caputo V, Muqit MM, Harvey K, et al. 2004. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 304:1158-1160 (Pubitemid 38661852)
83. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, et al. 2004. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44:601-607 (Pubitemid 39531225)
84. Paisan-Ruiz C, Jain S, Evans EW, Gilks WP, Simon J, et al. 2004. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44:595-600 (Pubitemid 39531224)
85. Shen J, Cookson MR. 2004. Mitochondria and dopamine; new insights into recessive parkinsonism. Neuron 43:301-304 (Pubitemid 39061122)
86. Canet-Aviles RM, Wilson MA, Miller DW, Ahmad R, McLendon C, et al. 2004. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 101:9103-9108 (Pubitemid 38781618)
87. Unoki M, Nakamura Y. 2001. Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway. Oncogene 20:4457-4465 (Pubitemid 32772428)
88. Greggio E, Jain S, Kingsbury A, Bandopadhyay R, Lewis P, et al. 2006. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23:329-341 (Pubitemid 44097032)
89. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, et al. 2000. Dopaminergic loss and inclusion body formation in α-Synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269 (Pubitemid 30112148)
90. Goldberg MS, Fleming SM, Palacino JJ, Cepeda C, Lam HA, et al. 2003. Parkin-deficient mice exhibit nigrostriatal deficits but not loss of dopaminergic neurons. J. Biol. Chem. 278:43628-43635 (Pubitemid 37345989)
91. Goldberg MS, Pisani A, Haburcak M, Vortherms TA, Kitada T, et al. 2005. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial parkinsonism-linked gene DJ-1. Neuron 45:489-496 (Pubitemid 40249861)
92. Kim RH, Smith PD, Aleyasin H, Hayley S, Mount MP, et al. 2005. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6- tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA 102:5215-5220 (Pubitemid 40503765)
93. Lee MK, Stirling W, Xu Y, Xu X, Qui D, et al. 2002. Human α-Synuclein-harboring familial Parkinson's disease-linked Ala-53/Thr mutation causes neurodegenerative disease with α-Synuclein aggregation in transgenic mice. Proc. Natl. Acad. Sci. USA 99:8968-8973 (Pubitemid 34693667)
94. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002. Neuronal α-synucleinopathy with severe movement disorder in mice expressing A53T human α-Synuclein. Neuron 34:521-533 (Pubitemid 34628750)
95. Von Coelln R, Thomas B, Savitt JM, Lim KL, Sasaki M, et al. 2004. Loss of locus coeruleus neurons and reduced startle in parkin null mice. Proc. Natl. Acad. Sci. USA 101:10744-10749 (Pubitemid 38955813)
96. Kitada T, Pisani A, Porter DR, Yamaguchi H, Tscherter A, et al. 2007. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. USA 104:11441-11446 (Pubitemid 47175159)
97. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM. 2002. Chaperone suppression of α-Synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868 (Pubitemid 34118369)
98. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. 2003. α-Synuclein locus triplication causes Parkinson's disease. Science 302:841 (Pubitemid 37339619)
99. Pesah Y, Burgess H, Middlebrooks B, Ronningen K, Prosser J, et al. 2005. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of α-Synuclein in Drosophila. Genesis 41:154-159 (Pubitemid 40656685)
100. Cha GH, Kim S, Park J, Lee E, Kim M, et al. 2005. Parkin negatively regulates JNK pathway in the dopaminergic neurons of Drosophila. Proc. Natl. Acad. Sci. USA 102:10345-10350 (Pubitemid 41023373)
101. Whitworth AJ, Theodore DA, Greene JC, Benes H, Wes PD, Pallanck LJ. 2005. Increased glutathione S-transferase activity rescues dopaminergic neuron loss in a Drosophila model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 102:8024-8029 (Pubitemid 40781056)
102. Imai Y, Soda M, Inoue H, Hattori N, Mizuno Y, Takahashi R. 2001. An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin. Cell 105:891-902 (Pubitemid 32635090)
103. Kitao Y, Imai Y, Ozawa K, Kataoka A, Ikeda T, et al. 2007. Pael receptor induces death of dopaminergic neurons in the substantia nigra via endoplasmic reticulum stress and dopamine toxicity, which is enhanced under condition of parkin inactivation. Hum. Mol. Genet. 16:50-60 (Pubitemid 46152544)
104. Meulener M, Whitworth AJ, Armstrong-Gold CE, Rizzu P, Heutink P, et al. 2005. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr. Biol. 15:1572-1577 (Pubitemid 41219597)
105. Menzies FM, Yenisetti SC, Min KT. 2005. Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr. Biol. 15:1578-1582
106. Yang Y, Gehrke S, Haque ME, Imai Y, Kosek J, et al. 2005. Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc. Natl. Acad. Sci. USA 102:13670-13675 (Pubitemid 41420906)
107. Clark IE, Dodson MW, Jiang C, Cao JH, Huh JR, et al. 2006. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441:1162-1166 (Pubitemid 43990738)
108. Park J, Lee SB, Lee S, Kim Y, Song S, et al. 2006. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441:1157-1161 (Pubitemid 43990737)
109. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, et al. 2006. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc. Natl. Acad. Sci. USA 103:10793-10798 (Pubitemid 44078055)
110. Wang D, Qian L, Xiong H, Liu J, Neckameyer WS, et al. 2006. Antioxidants protect PINK1- dependent dopaminergic neurons in Drosophila. Proc. Natl. Acad. Sci. USA 103:13520-13525 (Pubitemid 44380140)
111. Wu YR, Wang CK, Chen CM, Hsu Y, Lin SJ, et al. 2004. Analysis of heat-shock protein 70 gene polymorphisms and the risk of Parkinson's disease. Hum. Genet. 114:236-241 (Pubitemid 38208300)
112. Dong Z, Wolfer DP, Lipp HP, Bueler H. 2005. Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. Mol. Ther. 11:80-88 (Pubitemid 40012001)
113. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, et al. 2002. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 4:160-164
114. Chen L, Feany MB. 2005. α-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat. Neurosci. 8:657-663 (Pubitemid 40594208)
115. Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, et al. 2001. Ubiquitination of a new form of α-Synuclein by parkin from human brain: implications for Parkinson's disease. Science 293:263-269 (Pubitemid 32694735)
116. Haywood AF, Staveley BE. 2004. Parkin counteracts symptoms in a Drosophila model of Parkinson's disease. BMC Neurosci. 5:14
117. Petrucelli L, O'Farrell C, Lockhart PJ, Baptista M, Kehoe K, et al. 2002. Parkin protects against the toxicity associated with mutant α-Synuclein: Proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 36:1007-1019 (Pubitemid 36044504)
118. Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, et al. 2004. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an α-Synuclein rat model of Parkinson's disease. Proc. Natl. Acad. Sci. USA 101:17510-17515 (Pubitemid 39657434)
119. Kim RH, Peters M, Jang Y, Shi W, Pintilie M, et al. 2005. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 7:263-273 (Pubitemid 40568685)
120. Jansson B, Jankovic J. 1985. Low cancer rates among patients with Parkinson's disease. Ann. Neurol. 17:505-509 (Pubitemid 15019991)
121. Chan DC. 2006. Mitochondria: dynamic organelles in disease, aging, and development. Cell 125:1241-1252 (Pubitemid 43929096)
122. Li Z, Okamoto K, Hayashi Y, Sheng M. 2004. The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 119:873-887 (Pubitemid 40017692)
123. Bossy-Wetzel E, Barsoum MJ, Godzik A, Schwarzenbacher R, Lipton SA. 2003. Mitochondrial fission in apoptosis, neurodegeneration and aging. Curr. Opin. Cell Biol. 15:706-716 (Pubitemid 37487964)
124. Beal MF. 2003. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Ann. N. Y. Acad. Sci. 991:120-131 (Pubitemid 36793808)
125. Sacktor B. 1976. Biochemical adaptations for flight in the insect. Biochem. Soc. Symp. 41:111-131
126. Scherzer CR, Jensen RV, Gullans SR, Feany MB. 2003. Gene expression changes presage neurodegeneration in a Drosophila model of Parkinson's disease. Hum. Mol. Genet. 12:2457-2466 (Pubitemid 37220410)
127. Ghosh S, Feany MB. 2004. Comparison of pathways controlling toxicity in the eye and brain in Drosophila models of human neurodegenerative diseases. Hum. Mol. Genet. 13:2011-2018 (Pubitemid 39377825)
128. Gusella JF, MacDonald ME. 2000. Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat. Rev. Neurosci. 1:109-115
129. Marsh JL, Walker H, Theisen H, Zhu YZ, Fielder T, et al. 2000. Expanded polyglutamine peptides alone are intrinsically cytotoxic and cause neurodegeneration in Drosophila. Hum. Mol. Genet. 9:13-25 (Pubitemid 30145284)
130. Takeyama K, Ito S, Yamamoto A, Tanimoto H, Furutani T, et al. 2002. Androgen-dependent neurodegeneration by polyglutamine-expanded human androgen receptor in Drosophila. Neuron 35:855-864
131. Chen HK, Fernandez-Funez P, Acevedo SF, Lam YC, Kaytor MD, et al. 2003. Interaction of Akt-phosphorylated ataxin-1 with 14-3-3 mediates neurodegeneration in spinocerebellar ataxia type 1. Cell 113:457-468 (Pubitemid 36588749)
132. Emamian ES, Kaytor MD, Duvick LA, Zu T, Tousey SK, et al. 2003. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 38:375-387
133. Tsuda H, Jafar-Nejad H, Patel AJ, Sun Y, Chen HK, et al. 2005. The AXH domain of Ataxin-1 mediates neurodegeneration through its interaction with Gfi-1/Senseless proteins. Cell 122:633-644 (Pubitemid 41191160)
134. Chan HY, Warrick JM, Andriola I, Merry D, Bonini NM. 2002. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in Drosophila. Hum. Mol. Genet. 11:2895-2904
135. Steffan JS, Agrawal N, Pallos J, Rockabrand E, Trotman LC, et al. 2004. SUMO modification of Huntingtin and Huntington's disease pathology. Science 304:100-104 (Pubitemid 38451465)
136. Jackson GR, Salecker I, Dong X, Yao X, Arnheim N, et al. 1998. Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons. Neuron 21:633-642 (Pubitemid 28475514)
137. Sang TK, Li C, Liu W, Rodriguez A, Abrams JM, et al. 2005. Inactivation of Drosophila Apaf-1-related killer suppresses formation of polyglutamine aggregates and blocks polyglutamine pathogenesis. Hum. Mol. Genet. 14:357-372 (Pubitemid 40227371)
138. Gunawardena S, Her LS, Brusch RG, Laymon RA, Niesman IR, et al. 2003. Disruption of axonal transport by loss of huntingtin or expression of pathogenic polyQ proteins in Drosophila. Neuron 40:25-40 (Pubitemid 37222462)
139. Lee WC, Yoshihara M, Littleton JT. 2004. Cytoplasmic aggregates trap polyglutamine-containing proteins and block axonal transport in a Drosophila model of Huntington's disease. Proc. Natl. Acad. Sci. USA 101:3224-3229 (Pubitemid 38327762)
140. Szebenyi G, Morfini GA, Babcock A, Gould M, Selkoe K, et al. 2003. Neuropathogenic forms of huntingtin and androgen receptor inhibit fast axonal transport. Neuron 40:41-52 (Pubitemid 37229083)
141. Jin P, Zarnescu DC, Zhang F, Pearson CE, Lucchesi JC, et al. 2003. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in Drosophila. Neuron 39:739-747 (Pubitemid 37088087)
142. Mutsuddi M, Marshall CM, Benzow KA, Koob MD, Rebay I. 2004. The spinocerebellar ataxia 8 noncoding RNA causes neurodegeneration and associates with staufen in Drosophila. Curr. Biol. 14:302-308 (Pubitemid 38300207)
143. Houseley JM, Wang Z, Brock GJ, Soloway J, Artero R, et al. 2005. Myotonic dystrophy associated expanded CUG repeat muscleblind positive ribonuclear foci are not toxic to Drosophila. Hum. Mol. Genet. 14:873-883 (Pubitemid 40403282)
144. Gavin BA, Dolph MJ, Deleault NR, Geoghegan JC, Khurana V, et al. 2006. Accelerated accumulation of misfolded prion protein and spongiform degeneration in a Drosophila model of Gerstmann-Straussler- Scheinker syndrome. J. Neurosci. 26:12408-12414 (Pubitemid 44864505)
145. Min KT, Benzer S. 1999. Preventing neurodegeneration in the Drosophila mutant bubblegum. Science 284:1985-1988 (Pubitemid 29309445)
146. Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, et al. 2001. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 413:739-743 (Pubitemid 33009952)
147. Ravikumar B, Vacher C, Berger Z, Davies JE, Luo S, et al. 2004. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36:585-595 (Pubitemid 38715985)
148. Berger Z, Ravikumar B, Menzies FM, Oroz LG, Underwood BR, et al. 2006. Rapamycin alleviates toxicity of different aggregate-prone proteins. Hum. Mol. Genet. 15:433-442 (Pubitemid 43159895)
149. Auluck PK, Bonini NM. 2002. Pharmacological prevention of Parkinson disease in Drosophila. Nat. Med. 8:1185-1186
150. Mudher A, Shepherd D, Newman TA, Mildren P, Jukes JP, et al. 2004. GSK-3β inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol. Psychiatry 9:522-523 (Pubitemid 38903508)